Entire Transcript in Adobe Acrobat Format - National Reference ...

93
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
DR. HOLTZMAN: So I think we need to be -- you
know, as we look --
MR. CAPRON: The term of art is anonymized.
DR. HOLTZMAN: Well, okay. So as we went
through our discussion before we got to the issue of the
researcher being able to go back, for clinical purposes let
me call that, that you made a discovery should you be able
to go back to the patient and help them. Before we even
got to that whole issue the motivation for not having, let
me call them purely anonymized, the motivation for a notion
of encryption was that as epidemiological information
accrued over time to the sample that could be important to
the research and that we wanted that to be able to pass
through, okay.
So coming back to my example, from what I have
heard I come to you, all right -- by the way we have done
this. We have come to you, right, and said we want access
to the Framingham samples. We get them in from our
perspective, millennium's perspective, in anonymous
fashion, right. We do not know who the heck we are -- they
are.
But it would be really nice as we are doing our
research if additional longitudinal information accrues to
what for you is sample John Jones for me is sample